Drug Resistance in Leishmaniasis

Overview

Journal J Glob Infect Dis

Date 2010 Jul 8

PMID 20606973

Citations 92

Authors

Jaya Chakravarty

Shyam Sundar

Affiliations

Soon will be listed here.

Abstract

The treatment options of leishmaniasis are limited and far from satisfactory. For more than 60 years, treatment of leishmaniasis has centered around pentavalent antimonials (Sb(v)). Widespread misuse has led to the emergence of Sb(v) resistance in the hyperendemic areas of North Bihar. Other antileishmanials could also face the same fate, especially in the anthroponotic cycle. The HIV/ visceral leishmaniasis (VL) coinfected patients are another potential source for the emergence of drug resistance. At present no molecular markers of resistance are available and the only reliable method for monitoring resistance of isolates is the technically demanding in vitro amastigote-macrophage model. As the armametrium of drugs for leishmaniasis is limited, it is important that effective monitoring of drug use and response should be done to prevent the spread of resistance. Regimens of simultaneous or sequential combinations should be seriously considered to limit the emergence of resistance.

Citing Articles

Evaluation of the Anti-Leishmanial Activity of the Hydroalcoholic Extract of Green Algae (Spirogyra): Investigation of Weight Indicators (Lesion Size and Organ Weights) in BALB/c Mice.

Zarezadeh Mehrizi R, Bafghi A, Nasiri V, Sarafraz Ardakani M, Meybodi M, Zare-Zardini H Acta Parasitol. 2025; 70(1):51.

PMID: 39918617 DOI: 10.1007/s11686-025-00994-4.

Identification of novel inhibitors from as anti-leishmanial agents targeting DDX3-DEAD box RNA helicase of .

Gouri V, Roy G, Kanojia A, Singh S, Muthuswami R, Samant M 3 Biotech. 2024; 15(1):18.

PMID: 39711919 PMC: 11659541. DOI: 10.1007/s13205-024-04183-4.

Understanding American tegumentary leishmaniasis in urban Montes Claros, Brazil: insights from clinical, immunological and therapeutic investigations.

Lopes D, Lima J, Ribeiro K, Gomes C, Rocha R, Goncalves T Parasitology. 2024; 151(11):1260-1268.

PMID: 39523648 PMC: 11894006. DOI: 10.1017/S0031182024001057.

Synthesis of Hybrid Molecules with Imidazole-1,3,4-thiadiazole Core and Evaluation of Biological Activity on and .

Mijoba A, Parra-Gimenez N, Fernandez-Moreira E, Ramirez H, Serrano X, Blanco Z Molecules. 2024; 29(17).

PMID: 39274974 PMC: 11396972. DOI: 10.3390/molecules29174125.

Identification of PEX5-PTS1 Interaction Inhibitors through Fluorescence Polarization-Based High-Throughput Screening.

Phan T, Park K, Shum D, No J Molecules. 2024; 29(8).

PMID: 38675653 PMC: 11054337. DOI: 10.3390/molecules29081835.

References

Berman J . U.S Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis. Clin Infect Dis. 1999; 28(1):49-51. DOI: 10.1086/515086. View

Callahan H, Beverley S . Heavy metal resistance: a new role for P-glycoproteins in Leishmania. J Biol Chem. 1991; 266(28):18427-30. View

Firooz A, Khamesipour A, Ghoorchi M, Nassiri-Kashani M, Eskandari S, Khatami A . Imiquimod in combination with meglumine antimoniate for cutaneous leishmaniasis: a randomized assessor-blind controlled trial. Arch Dermatol. 2006; 142(12):1575-9. DOI: 10.1001/archderm.142.12.1575. View

Mishra M, Biswas U, Jha D, Khan A . Amphotericin versus pentamidine in antimony-unresponsive kala-azar. Lancet. 1992; 340(8830):1256-7. DOI: 10.1016/0140-6736(92)92952-c. View

Sundar S, Jha T, Thakur C, Mishra M, Singh V, Buffels R . Low-dose liposomal amphotericin B in refractory Indian visceral leishmaniasis: a multicenter study. Am J Trop Med Hyg. 2002; 66(2):143-6. DOI: 10.4269/ajtmh.2002.66.143. View

Alvar J, Canavate C, Jimenez M, Laguna F, Lopez-Velez R, Molina R . Leishmania and human immunodeficiency virus coinfection: the first 10 years. Clin Microbiol Rev. 1997; 10(2):298-319. PMC: 172921. DOI: 10.1128/CMR.10.2.298. View

Laguna F, Videla S, Jimenez-Mejias M, Sirera G, Torre-Cisneros J, Ribera E . Amphotericin B lipid complex versus meglumine antimoniate in the treatment of visceral leishmaniasis in patients infected with HIV: a randomized pilot study. J Antimicrob Chemother. 2003; 52(3):464-8. DOI: 10.1093/jac/dkg356. View

Sundar S, Thakur B, Tandon A, Agrawal N, Mishra C, Mahapatra T . Clinicoepidemiological study of drug resistance in Indian kala-azar. BMJ. 1994; 308(6924):307. PMC: 2539260. DOI: 10.1136/bmj.308.6924.307. View

Maarouf M, Adeline M, Solignac M, Vautrin D . Development and characterization of paromomycin-resistant Leishmania donovani promastigotes. Parasite. 1998; 5(2):167-73. DOI: 10.1051/parasite/1998052167. View

10.

Escobar P, Matu S, Marques C, Croft S . Sensitivities of Leishmania species to hexadecylphosphocholine (miltefosine), ET-18-OCH(3) (edelfosine) and amphotericin B. Acta Trop. 2002; 81(2):151-7. DOI: 10.1016/s0001-706x(01)00197-8. View

11.

Sundar S, Rai M, Chakravarty J, Agarwal D, Agrawal N, Vaillant M . New treatment approach in Indian visceral leishmaniasis: single-dose liposomal amphotericin B followed by short-course oral miltefosine. Clin Infect Dis. 2008; 47(8):1000-6. DOI: 10.1086/591972. View

12.

Olliaro P, Sundar S . Anthropometrically derived dosing and drug costing calculations for treating visceral leishmaniasis in Bihar, India. Trop Med Int Health. 2009; 14(1):88-92. DOI: 10.1111/j.1365-3156.2008.02195.x. View

13.

Teklemariam S, Hiwot A, Frommel D, Miko T, Ganlov G, Bryceson A . Aminosidine and its combination with sodium stibogluconate in the treatment of diffuse cutaneous leishmaniasis caused by Leishmania aethiopica. Trans R Soc Trop Med Hyg. 1994; 88(3):334-9. DOI: 10.1016/0035-9203(94)90106-6. View

14.

Molina R, Gradoni L, Alvar J . HIV and the transmission of Leishmania. Ann Trop Med Parasitol. 2003; 97 Suppl 1:29-45. DOI: 10.1179/000349803225002516. View

15.

Lira R, Sundar S, Makharia A, Kenney R, Gam A, Saraiva E . Evidence that the high incidence of treatment failures in Indian kala-azar is due to the emergence of antimony-resistant strains of Leishmania donovani. J Infect Dis. 1999; 180(2):564-7. DOI: 10.1086/314896. View

16.

Sundar S, Agrawal N, Sinha P, Horwith G, Murray H . Short-course, low-dose amphotericin B lipid complex therapy for visceral leishmaniasis unresponsive to antimony. Ann Intern Med. 1997; 127(2):133-7. DOI: 10.7326/0003-4819-127-2-199707150-00007. View

17.

Peters W . The treatment of kala-azar--new approaches to an old problem. Indian J Med Res. 1981; 73 Suppl:1-18. View

18.

Berman J . Activity of imidazoles against Leishmania tropica in human macrophage cultures. Am J Trop Med Hyg. 1981; 30(3):566-9. DOI: 10.4269/ajtmh.1981.30.566. View

19.

Mukhopadhyay R, Dey S, Xu N, Gage D, Lightbody J, Ouellette M . Trypanothione overproduction and resistance to antimonials and arsenicals in Leishmania. Proc Natl Acad Sci U S A. 1996; 93(19):10383-7. PMC: 38393. DOI: 10.1073/pnas.93.19.10383. View

20.

Singh N, Singh R, Sundar S . Novel mechanism of drug resistance in kala azar field isolates. J Infect Dis. 2003; 188(4):600-7. DOI: 10.1086/377133. View